Fig. 7.
The inhibitory effects of BJ-1113 on xenografted MDA-MB-231 tumor growth on CAM and in nude mice. a, b MDA-MB-231 human breast cancer cells (2 × 106 cells/CAM) were inoculated on top of CAM; drug were mixed with cell suspension before inoculation. The tumor growth and angiogenesis shown in a were quantitated and are expressed as the numbers of new vessel branches formed and tumor weights (b). A representative tumor mass isolated from CAM: 1, vehicle control; 2, LY310762-treated group; 3, SB269970-treated group; 4, wortmannin (Wort) treated group; and 5, BJ-1113-treated group. *P < 0.05 vs. PBS-treated controls. # P < 0.05 vs. SB269970 or Wort treated cells. c-e. BALB/c nude mice bearing MDA-MB-231-effluc cells were administered intraperitoneally with cisplatin or BJ-1113 for 19 consecutive days. In each group, six mice were used. c Tumor growth was monitored by measuring tumor size. d Bioluminescent imaging of tumors was performed as described in Material and Methods; in addition, e tumor tissues were isolated and their weights were recorded. *P < 0.05 vs. vehicle-treated control mice. # P < 0.05 vs. cisplatin-treated mice. f Unlike cisplatin, treatment with BJ-1113 for 19 days did not alter body weights. g BJ-1113 inhibited TPH1 and VEGF protein expression in MDA-MB-231 effluc tumor. *P < 0.05 vs. vehicle-treated control mice